Archives: Agenda

PANEL DISCUSSION: Identifying patients as equal partners and including their voice in all stages of drug development

  • Acknowledging the value that patients can bring to every stage of the drug development pathway
  • Engaging patients and advocacy groups early on in the clinical trial design process
  • How minimizing participant burden leads to on-time enrollment and completion
  • Combining patient perspectives with those of healthcare professionals to create a holistic trial model
  • Highlighting how to compensate patients

Moderator: Amanda Murphy, Senior Director, Data Intelligence & Solutions, GlobalData

PANEL DISCUSSION: Where is the clinical trial industry headed?

  • Moving studies forward on unknown territory: Funding clinical trials amidst recent research policy changes and abrupt NIH cuts
  • Shining light on the changing scope of the FDA: Discussion of the latest changes under the new administration including years of critical DEI work
  • Technological developments into 2026 and beyond: what changes can we expect to see in the next 3-5 years?
  • Navigating the constantly evolving vendor and CRO landscape as a small to mid-sized sponsor company

Moderator: Robert Loll, SVP, Business Development & Strategic Planning, Praxis

 

From sample to strategy: Holistic laboratory partnership to enable delivery of modern trial designs

  • Integrating central lab expertise early in trial design to avoid fragmented workflows and costly delays
  • Enhancing trial efficiency and biomarker strategy through proactive collaboration with laboratory partners
  • Positioning lab providers as co-authors of research success, offering insights on biomarkers, assays, sample logistics, and data flow
  • Ensuring protocols are both scientifically robust and operationally feasible by embedding lab considerations from the outset